Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zolbetuximab + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Zolbetuximab + nab-paclitaxel + gemcitabine is a combination therapy under clinical investigation for previously untreated, metastatic, Claudin 18.2 (CLDN18.2)-positive pancreatic adenocarcinoma. Zolbetuximab is an IgG1 monoclonal antibody that specifically binds to CLDN18.2 on tumor cells, leading to tumor cell lysis through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Nab-paclitaxel is an albumin-bound formulation of paclitaxel, a microtubule inhibitor, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. The combination aims to enhance anti-tumor activity by targeting the tumor antigen CLDN18.2 and disrupting cell division and DNA replication in cancer cells[1][3]. Clinical development is in phase II, focusing on the first-line treatment of CLDN18.2-positive metastatic pancreatic adenocarcinoma[3].
- Other names
- zolbetuximab + nab-paclitaxel + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))Claudin 18.2
Beyond the preview
Go deeper on zolbetuximab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zolbetuximab + nab-paclitaxel + gemcitabine.